• Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

    Источник: Nasdaq GlobeNewswire / 14 июн 2024 03:01:00   America/New_York

    N/A
Опубликовать